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Abstract
Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation and a variable course
associated with various underlying mechanisms that can differ between individuals. Patients with asthma can
therefore exhibit different phenotypes, a term used to define the observable characteristics of an organism resulting
from the interaction between its genetic makeup and the environment. The heterogeneity of asthma has received
a large amount of attention in the last few years in order to better tailor treatment according to the different clinical and
biological phenotypes of the disease. Specific asthma phenotypes may require an approach to treatment sometimes
different from that recommended by current guidelines, so a personalized approach to asthma pharmacotherapy is
recommended. Growing evidence suggests that leukotrienes play an important role in the pathogenesis of bronchial
asthma. The mechanisms of action of leukotriene-receptor antagonists theoretically predict a good response in some
asthma “phenotypes”.In this article we have performed an analysis of the recent literature (controlled clinical trials and
real-life studies) about a possible selective intervention with Montelukast in specific asthma phenotypes.
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Background
Asthma is one of the most common chronic conditions
in the world and the most common non-communicable
disease among children [1]; according to the Global
Burden of Disease Study [2], asthma affects more than
300 million people worldwide. In Europe alone, asthma
affects 30 million people [3] and is associated with a sig-
nificant socioeconomic burden [4]. Although asthma has
long been recognized as a heterogeneous disease [5],
only in recent years it is seen not as single disease but
rather as a series of multiple phenotypes, each defined
by an unique interaction between genetic and environ-
mental factors [6]. According to the landmark study of
Wenzel [7], phenotype categorizations generally focus
on clinical, trigger-related, or inflammatory characteristics,
such as eosinophilic, age at onset, treatment-resistant,
aspirin-related, obesity-related, or allergic asthma Proposed
asthma phenotypes can be further refined into subtypes as
defined by a distinct functional or pathophysiological
mechanism, which are known as “endotypes” [8]. A precise
definition of asthma phenotypes is becoming increasingly
important, because recognition of specific sub-phenotypes
may further improve our understanding of pathophysio-
logic mechanisms and treatment response, especially in
patients who respond poorly to current therapies [9]. Trad-
itional asthma medications did not work in all patients and
there is marked patient-to-patient variability in the thera-
peutic response; inhaled glucocorticoids (ICS) are used
every day, as monotherapy or add-on therapy, by millions
of patients with asthma, but about one in three patients
may not benefit from this treatment [10]; there is a consid-
erable amount of evidence supporting the concept that
some asthma phenotypes seem sensitive to leukotriene re-
ceptor antagonists (LTRAs), especially in a real-life setting
[11]. Montelukast has proven to be particularly effective in
exercise-induced asthma and in asthma associated with
allergic rhinitis. Other phenotypes where montelukast is
effective include asthma in obese patients, asthma in
smokers, aspirin-induced asthma and viral-induced wheez-
ing episodes [12] (Fig. 1). In this article we have performed
an analysis of the recent literature (controlled clinical trials,
but also pragmatic trials and observational studies,
designed to better reflect aspects of routine care than
most randomised controlled trials) about the role of* Correspondence: macottini@alice.it
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Montelukast in asthma therapy, especially in some
specific asthma phenotypes.
Montelukast, a once-daily leukotriene receptor antagonist,
in the treatment of chronic asthma
The role of cysteinyl leukotrienes (CysLTs) as key media-
tors and modulators in the pathogenesis of asthma has
been reported in both experimental and clinical settings
[13]. CysLTs are produced predominantly by cells of the
innate immune system, especially basophils, eosinophils,
mast cells, and monocytes/macrophages [14]. The inter-
action of cysLTs with their type 1 counter-receptors on
cells of the innate immune system cause smooth muscle
contraction, exacerbate bronchial hyperresponsiveness,
impair mucociliary clearance, enhance mucus secretion,
increase vascular permeability and also drive Th2- cell-
mediated eosinophilic airway inflammation [14].
The bronchospastic effect of CysLTs is greater than
that of histamine or methacholine in human airways,
both in vivo and in vitro. The CysLTs play an important
role in the airway remodeling seen in persistent asthma,
that includes increases of airway goblet cells, mucus,
blood vessels, smooth muscle, myofibroblasts, and airway
fibrosis [15]. Evidence from a mouse model of asthma
demonstrated that CysLT1 receptor antagonists inhibit
the airway remodeling processes, including eosinophil
trafficking to the lungs, eosinophil degranulation, TH2
cytokine release, mucus gland hyperplasia, mucus hy-
persecretion, smooth muscle cell hyperplasia, collagen
deposition, and lung fibrosis [15]. Additional interest in
the therapeutic potential of CysLT1 receptor antago-
nists derives from the facts that neither LT synthesis
[16], nor receptor expression [17] is inhibitable by cor-
ticosteroids. The recognition of the role of CysLTs in
the immunopathogenesis of asthma prompted the de-
velopment of selective antagonists. Among CysLT1 re-
ceptor antagonists, montelukast has shown the best
efficacy and safety profile, and it has become the most
widely studied antileukotriene compound. Montelukast
has been reported to possess secondary anti-inflammatory
properties, apparently unrelated to conventional antagon-
ism of cysteinyl leukotriene receptors, suggesting that this
agent may have a broader spectrum of anti-inflammatory
activities than originally thought [18]. According to results
of randomised controlled trials and systematic reviews,
Montelukast, when used as monotherapy or added to in-
haled corticosteroids, is able to reduce rescue treatment
requirements, improve pulmonary function, and reduce
symptoms and risk of exacerbations in adults and children
with asthma [19, 20]. Guidelines recommend the use of
LTRAs as monotherapy for patients with mild persistent
asthma, as an alternative or as add-on therapy to ICSs,
and as an alternative to either increasing the ICS dose or
adding a long-acting 2-agonist [21]. Systematic reviews
comparing anti-leukotriene agents and inhaled corticoste-
roids (ICS) in the management of chronic asthma in
adults and children concluded that, as monotherapy, ICS
display superior efficacy to anti-leukotrienes (particularly
in patients with moderate airway obstruction) [22], en-
dorsed the current guideline position that ICS should be
the first-choice preventer therapy in patients initiating
maintenance asthma therapy, with leukotriene modifiers
as an option [21]. Although RCTs are the cornerstone of
evidence-based research, their generalizability to the clin-
ical practice setting is questionable, because recruitment
often includes only patients with no (or negligible) co-
morbid illnesses or concurrent medications and those
with good inhaler technique and high adherence to study
therapies, questioning the relevance of their findings for
the wide range of patients managed in routine practice
[23]; due to their strict inclusion criteria, RCTs exclude
approximately 95 % of asthma routine care populations
[24]. Real-life studies (e.g., naturalistic or pragmatic clin-
ical trials and observational studies), that include a more
heterogeneous asthma population, provide opportunity to
explore the interaction between comorbidities, lifestyle
Fig. 1 Possibile relationships between Montelukast and asthma
phenotypes/endotypes on the basis of controlled clinical trials and
real-life studies
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factors, patient characteristics and asthma treatment out-
comes [11]; real life studies have limitations, primarily
stemming from the lack of randomization (the lack of pa-
tient selection, one of the most distinctive characteristics
of real life studies, makes it impossible to avoid un-
measured confounding factors) and the need to apply
the indications only within the local geographic context.
Randomized RCTs thus remain the “gold standard” for
evaluating treatment outcomes, but observational studies
and pragmatic trials can complement classical RCTs by
providing data more relevant to the circumstances under
which medicine is routinely practiced, providing practical
guidance for clinicians [25]. There is growing evidence
that efficacy of Montelukast is higher in some asthma
phenotypes seem sensitive to Montelukast, especially in a
real-life setting [11]. Price et al. in a pragmatic, “real
world” study (primary care practices) published in the
New England Journal of Medicine, evaluated patients 12
to 80 years of age who had impaired asthma-related qual-
ity of life) or inadequate asthma control [26]. This prag-
matic trial and health economic evaluation found LTRAs
to be equivalent to inhaled corticosteroids at Global Initia-
tive for Asthma (GINA) step 2 and to add-on long-
acting β-agonists (LABAs) at GINA step 3. The pri-
mary outcome of the trial was a patient-focused
quality-of-life outcome, the Mini Asthma Quality of
Life Questionnaire at 2 months. No significant differ-
ences in Mini Asthma Quality of Life Questionnaire
were reported between LTRAs and ICSs (at GINA
step 2) or add-on LTRAs and add-on LABAs (at
GINA step 3) after 2 months of treatment. Recently,
Ann Chen Wu et al. showed that the risk of emer-
gency department visits, hospitalizations, and oral
corticosteroids use did not differ between children
who initiated leukotriene antagonist and those who
initiated inhaled corticosteroid in five health plans
and a state Medicaid population [27]. Medication ad-
herence could influence the effectiveness of regimens
in practice because adherence to medications in clin-
ical trials is higher than in real-life practice [28]. As
with all asthma medications, therapeutic responses to
montelukast are highly variable, with some patients
responding preferentially to leukotriene modifiers vs
other medications [29]; mounting evidence suggests
that this heterogeneity in treatment response to mon-
telukast is due, in part, to patient genetics [30]. There
is an increasing appreciation of heterogeneity within
asthma based primarily on cluster analyses, molecular
phenotyping, biomarkers, and differential responses to tar-
geted and non targeted therapies. These studies have led
to successful therapeutic trials of molecularly targeted
therapies in defined phenotypes (anti-IL-5,anti IL-13,etc)
[31]. At the present time, there are no specific bio-
markers that can definitively predict responsiveness to
anti-LT agents, thus explaining the importance of cur-
rently using clinical characteristics to identify responders
and the performance of a therapeutic trial in individual
patients [32].
Montelukast: which role in the heterogeneity of asthma?
Patients with specific phenotypes/endotypes, “real-life”
comorbidities and lifestyle factors receiving usual care
often have different responses to antiasthmatic drugs.
The identification of subgroups of asthmatic patients
who respond to CysLT [1] receptor antagonists is relevant
for asthma management as the response to these drugs is
variable [32].
Asthma and rhinitis
Comorbidity of asthma and rhinitis has been well docu-
mented [33], and evidence is accumulating to support
more than a coincidental association, suggesting a link
between upper and lower airway disease and the hypoth-
esis that asthma and rhinitis represent a systemic disease
[34]. Patients with rhinitis have an increased risk of de-
veloping asthma [35]. Poorly controlled allergic rhinitis
may be associated with worsening asthma control over
time [36]. Allergic rhinitis is a very important clinical
characteristic of “allergic asthma” endotype [37]. Grow-
ing evidence suggests that leukotrienes play an import-
ant role in the pathogenesis of allergic rhinitis [38]. A
systematic review and meta-analysis of 11 large RCTs
showed that leukotriene receptor antagonists were better
than placebo and as effective as antihistamines, but less
effective than nasal corticosteroids in improving symp-
toms and quality of life in patients with seasonal allergic
rhinitis [39]. Nayak et al. conducted a systematic review
of studies that have evaluated montelukast in the treat-
ment of seasonal AR (SAR) and perennial AR (PAR),
with and without concomitant asthma. In patients with
AR comorbid with asthma, montelukast treatment re-
sulted in significant improvements in both diseases,
compared with placebo and allowed a reduction in the
use of asthma medication [40]. In the Clinical Outcomes
with Montelukast as a Partner Agent to Corticosteroid
Therapy (COMPACT) examined whether asthma patients
with comorbid allergic rhinitis responded differently
to budesonide plus montelukast than patients without
comorbid allergic rhinitis in terms of asthma control
(lung function). In the subgroup of asthmatic patients
with AR, a combined treatment approach that included
montelukast and budesonide provided significantly greater
efficacy in reducing airflow obstruction compared with
doubling the dose of budesonide [41]. Despite the strong
association between rhinitis and asthma, patients with
rhinitis are often excluded from cRCTs of asthma therap-
ies [42]. Several observational studies evaluate the efficacy
and safety of montelukast in patients with both asthma
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and allergic rhinitis in a real-life setting. In a 12-month,
open-label study, Virchow et al. enrolled 1681 patients
with mild to moderate asthma insufficiently controlled by
ICS or ICS + LABA. Patients received montelukast 10 mg
qd as add-on therapy and were evaluated at months 3, 6,
9, and 12. Asthma Control Test (ACT) score in the overall
population was the primary endpoint; add-on montelukast
demonstrated significant improvement in asthma symp-
toms over 12 months in all patients in the study, but pa-
tients who had allergic rhinitis demonstrated numerically
better ACT scores compared with those who did not have
allergic rhinitis. The authors concluded that comorbid
allergic rhinitis was a strong indicator of better control
with add-on montelukast [43] Recently, Ann Chen Wu et
al. showed, in five health plans and a state Medicaid popu-
lation, that children with asthma and allergic rhinitis
treated with LTRAs were less likely to experience ED visits
(hazard ratio 0.44) compared with the subjects treated
with ICS [27]. The results of many “real life” studies sug-
gest that a treatment approach with montelukast, target-
ing the airway inflammation common to both diseases,
may be beneficial for the large proportion of asthma pa-
tients who also suffer from allergic rhinitis. In conclusion,
treatment guidelines have recognized that asthma and AR
are linked conditions of “united airways disease” and rec-
ommend that patients with asthma be evaluated for AR
and vice versa. These guidelines support a combined ap-
proach to treating both conditions [33]. Two International
consensus reports concluded that Montelukast may be
particularly useful in children when the patient has con-
comitant rhinitis [44, 45].
Exercise-induced bronchoconstriction
According to asthma treatment guidelines [21], the pres-
ence of activity limitation due to exercise-related symp-
toms is a key factor for worse asthma control. Exercise-
induced bronchoconstriction (EIB) is accompanied by
release of mediators such as PGs, CysLTs C4, D4, and
E4 and histamine [46]. Several studies with montelukast
have shown beneficial effects in adults and children aged
as young as 6 years with EIB. The first demonstrations
of the efficacy of montelukast in EIB were obtained in
the mid-1990s, when the results of studies of the protect-
ive effect of montelukast on bronchoconstriction induced
by exercise were published [47–49]. It these studies, toler-
ance was not seen with continued montelukast treatment.
The effect of a single dose of montelukast in patients with
mild asthma who only have EIB was evaluated in a ran-
domized, crossover, double-blind study study [50]: an
initial single dose of montelukast was able to provide
significant protection against EIB as soon as 2 h, with
persistent benefit up to 24 h. Several randomized con-
trol trials specifically evaluated the efficacy of montelu-
kast in EIB in children. In a double blind, placebo-
controlled, 3 day doses, crossover study, Montelukast
assured protection against exercise-induced broncho-
constriction from the first through the eighth hour
from the first day of treatment. However, individual
susceptibility to protection was evident since some in-
dividuals were not protected at any time [51]. de Bene-
dictis et al. evaluated tolerance to the protective effect
of montelukast in exercise-induced bronchoconstriction
in children at different time-points over a 4-week treat-
ment period. Montelukast was significantly more pro-
tective than placebo against EIB at each time, with no
tolerance to the bronchoprotective effect [52]. This as-
pect is particularly relevant for children, who tend to
be active at frequent and irregular intervals throughout
the day, and who therefore may benefit from around-
the-clock pharmacologic protection. Only few studies
have compared regular treatment with Montelukast
against that with ICS.Stelmach et al. compared effects
of: a) the inhaled ICS budesonide alone, b) budesonide
plus the long-acting β2-agonist formoterol, c) budeso-
nide plus montelukast, d) montelukast alone, and e)
placebo, in children ages 6–18 with EIB, finding the
greatest protection from EIB in either of the two groups
given Montelukast [53]. In a crossover study, under-
taken in a small group of only 20 patients to compare
the ability of both montelukast and budesonide to pro-
tect patients from EIB, both budesonide and montelu-
kast significantly reduced the decrease in FEV1 after
exercise with respect to the baseline condition of no
therapy (P = 0.0001). Overall, budesonide offered better
protection than did montelukast (P = 0.01); however,
considerable individual variations in the responses to
both budesonide and montelukast were observed [54].
Beta 2-agonists taken immediately before exercise pro-
vide significant protection against exercise- induced
asthma (EIA) in most patients. However, when they are
taken daily, there are some negative aspects regarding
severity, control, and recovery from EIB. Daily use of
ß2 agonists causes desensitisation of ß2 receptors, lead-
ing to enhances mediator release and down regulation
of numbers. The mast cell are more affected than
muscle, so that duration of protective effect is shorter
than the bronchodilator effect [55]. Several studies with
LABAs have shown a protective effect on EIB of 10–
12 h, but with regular use of LABAs tolerance is com-
mon, resulting in a decrease in duration of protection
[56, 57]. Several RCTs compared short and long-term
protection against EIB of long-acting β2 agonists and
Montelukast. Fogel et al. evaluated the effect of montelu-
kast or inhaled salmeterol, added to inhaled fluticasone in
reducing FEV1 after a standardized exercise challenge and
response to rescue bronchodilation with albuterol in chil-
dren aged 6 to 14 years with persistent asthma and EIB.
The Authors showed that Montelukast, compared with
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salmeterol, significantly reduced the decrease in FEV1
after exercise and median time to recovery. Response to
albuterol rescue after exercise challenge was significantly
greater with montelukast [58]. In a double-blind, placebo-
controlled study performed at 16 centers in the United
States, patients with asthma whose symptoms were
uncontrolled on low-dose inhaled fluticasone taking
montelukast had significantly greater protection from
an exercise-induced decrease in FEV1 than those taking
salmeterol (P < 0.001). The authors pointed out that con-
cerns in the salmeterol group regarding long-acting β2
-agonists decreased the effects of short-acting β2 -agonists
and tachyphylaxis with downregulation of airway smooth
muscle receptor numbers [59]. In a comparative system-
atic review of RCTs in children, the authors conclude that
compared with LABAs, LTRAs produce persistent attenu-
ation of EIB and possess an additional effect with rescue
short-acting adrenoceptor agonists therapy in asthmatic
patients with persistent EIB [60]. It is important to re-
member that not all patients respond equally. Therefore
no matter what treatment is chosen, it is important to
have a reevaluation of patient with EIB in 2–4 weeks, as
responses vary [61].
Active smoking
Available information suggest that proportion of patients
with asthma who smoke may be similar to that of the
general population (20 to 35 %). Increased morbidity
and mortality have been reported in asthmatic individ-
uals who smoke [62]. Cigarette smoking among asth-
matic patients is associated with worsening symptoms
and poorer asthma control [63]. In asthma treatment
guidelines, inhaled corticosteroids are considered the
standard of care; however, these guidelines are based on
evidence from randomised clinical trials that exclude pa-
tients who smoke cigarettes and RCT inclusion criteria
often resulting in exclusion of not only current smokers,
but also any patients with a history of ten pack years or
more [64]. Active smoking in asthma is associated with
impaired response to corticosteroids [65]. Current asthma
guidelines do not provide specific treatment advice for
smoking asthmatic patients [64]. The use of LTRAs is a
treatment option with potential utility in smoking asth-
matics. Evidence has suggested that cigarette smoking
induces production of cysteinyl leukotrienes, possibly
through COX-1 induction, which could be expected to
worsen asthma [66]. Montelukast could be an option in
smoking asthmatics, especially if their treatment re-
sponse to corticosteroids is blunted. Lazarus et al. in a
multicenter, placebo-controlled, double-blind, double-
dummy, crossover trial, found a blunted response to
ICSs, confirming the presence of corticosteroid insensi-
tivity in patients with asthma who smoke; conversely,
Montelukast produced a statistically significant increase
in a.m. peak flow and a decrease in peak flow variability
in smokers, and these changes were significantly greater
than its effects seen in nonsmokers [67]. More recently,
in a large double-blind asthma RCT involving asth-
matic smokers, Price et al. [68] evaluated, 10 mg/day
montelukast and 250 mg of medium-dose fluticasone
propionate twice daily and placebo. Both 10 mg/day
montelukast and 250 mg of fluticasone propionate
twice daily significantly increased the mean percentage
of days with asthma control compared with placebo.
The difference between montelukast and fluticasone
was not statistically significant, which contrasts studies
in nonsmokers showing superiority of inhaled corticoste-
roids to montelukast. Smoking history and exposure ap-
peared to play a role in response to therapy: patients with
a smoking history of less than the median value of 11 pack
years tended to show more benefit of fluticasone, whereas
those with a smoking history of greater than 11 pack years
tended to show more benefit with montelukast.
Passive smoking
Many asthmatic patients (particularly children) are ex-
posed to cigarette smoke, known to cause corticosteroid
resistance [69]. In asthmatic children, exposure to to-
bacco smoke (higher cotinine levels) is associated with
higher urinary LTE(4) [70]. Rabinovitch et al. followed
twenty-seven schoolchildren for 5 months with measure-
ments of urinary leukotriene E4 (LTE(4)), cotinine, frac-
tional exhaled nitric oxide (FENO), and monitored
albuterol use. After a baseline run-in, children were ran-
domized to receive daily montelukast or placebo without
change in their current controller medications. The au-
thors showed that Montelukast was more effective in
children exposed to tobacco smoke, suggesting that the
CysLT pathway might play an important role in mediating
asthma-related health effects related to secondhand
smoke (SHS) exposure [71]. Interestingly, an increased
urinary leukotriene E4 level was the only factor that iden-
tified the children at high risk for asthma exacerbations.
Obesity
Obesity has been shown to be risk factor for developing
asthma. Obese asthmatics reports worse asthma control
despite traditional asthma therapy, worse asthma-specific
quality of life, and higher rates of healthcare utilization
[72]. Both adult and pediatric studies indicate that obese
asthmatics are less responsive to glucocorticoids, the
mainstay of asthma controller therapy [73, 74]. Further-
more, obesity is associated with a decreased broncho-
dilator responsiveness [75]. Obesity is associated with
increased expression of 5-lipoxygenase (5-LO) pathway
and key members of the LT synthesis pathway are overex-
pressed in adipose tissue during obesity, resulting in in-
creased LTs levels in this tissue [76]. Increased Leukotrienes
Marcello and Carlo Asthma Research and Practice  (2016) 2:11 Page 5 of 12
production has been observed in obese asthma patients
[77]. In a large retrospective analysis of data from four ran-
domized trials comprising 3.037.
Three thousand thirty-seven adults with moderate to
severe asthma, Peters-Golden et al. and suggested that
obese patients, who are less responsive to ICS than are
nonobese subjects, may be relatively more responsive to
montelukast. In lean patients, beclomethasone resulted
in a higher percentage of asthma control data than did
montelukast, at 18.6 % versus 9.5 % (P < 0.001). How-
ever, the beneficial effect of the inhaled corticosteroid
versus the leukotriene modifier became less as BMI in-
creased, with a comparative effect of 18.8 % versus
15.7 % in overweight (P = 0.25), and 13.9 versus 13.4
(P = 0.90) in obese adults. Compared to ICS, the authors
concluded that obese patients with asthma had a better re-
sponse to montelukast. [78] However, in two other post
hoc analyses, comparing ICS or ICS/LABA versus monte-
lukast among the overweight and obese, ICS and ICS/
LABA were consistently more effective than montelukast
in all BMI catergories [79].
Aspirin-exacerbated respiratory disease (AERD)
AERD is an “adult-onset” asthma phenotype with high
prevalence, associated with chronic hyperplastic rhinosi-
nusitis, nasal polyps, and asthma attacks after ingestion
of aspirin and other nonselective COX inhibitors that
block COX-1 [80]. The prevalence of AERD in adult
asthmatic populations is approximately 10 to 25 % [81].
This asthma phenotype is present most often in patients
with severe asthma [82]. Aspirin-exacerbated respiratory
disease is explained in part by overexpression of 5-
lipoxygenase and leukotriene C4 synthase (LTC4S), result-
ing in constitutive overproduction of cysteinyl leukotrienes
(CysLTs) and driving the surge in CysLT production that
occurs with aspirin ingestion [80]. Furthermore, AERD is
characterized by the overexpression of CysLT receptors.
Subjects with aspirin-intolerant asthma had higher baseline
levels of CysLTs in saliva, sputum, blood ex vivo and urine
than subjects with aspirin-tolerant asthma [80]. These find-
ings support a global and specific increase in CysLT pro-
duction in aspirin-intolerant asthma. This asthma
phenotype is frequently poorly responsive to inhaled ste-
roids and, as a group, patients with AERD appear to benefit
substantially from anti-LT agents. Dahlen et al. investigated
whether addition of the leukotriene receptor antagonist
montelukast was of therapeutic benefit in a group of 80
aspirin-intolerant patients with asthma of whom 90 %
already were treated with moderate to high doses of gluco-
corticosteroids [83]. The group receiving montelukast
showed a remarkable improvement of their asthma,
whereas the group given placebo showed no change. The
improved pulmonary function in the group receiving mon-
telukast was associated with fewer asthma symptoms and
fewer asthma exacerbations. Mastalerz et al. compared the
clinical response to montelukast in aspirin-intolerant asth-
matics (AIAs) and aspirin-tolerant asthmatics (ATAs). Fol-
lowing a 3-week montelukast 10 mg day-1 treatment
compared with placebo, both groups showed a similar sig-
nificant improvement in asthma control, morning and
evening peak expiratory and quality of life [84]. Recently, a
survey analyzed perceptions and quality of life in patients
living with AERD and queried patient observations of
treatment effectiveness [85]. Patients do not appear to be
satisfied with current treatment options as evidenced by
persistent symptoms, adverse effect on quality of life, and
pursuit of various alternative treatment options. Of all the
treatments offered, aspirin desensitization was reported to
be the most beneficial, followed by a leukotriene receptor
antagonist and a combination of medications. In this sur-
vey, half of the respondents on a leukotriene receptor an-
tagonist found it to be helpful. Micheletto et al. [86]
studied 36 nonsmoker subjects with AIA and performed a
nasal provocation test with lysine-aspirin (L-ASA) in base-
line and after a 4-week Montelukast 10 mg or placebo
treatment and showed that Montelukast, but not placebo,
improves nasal function and nasal response to Aspirin sub-
stantially in ASA-sensitive asthmatics. In conclusion, the
results of these studies and the role of constitutive overpro-
duction of cysteinyl leukotrienes in the pathogenesis of dis-
ease, support the view that treatment with montelukast,
generally as add-on therapy, can improve asthma control
and nasal symptoms in asthmatic patients with AERD.
Asthma in elderly patients
Recent epidemiologic studies have indicated that asthma
is highly frequent in the elderly population with a preva-
lence ranging from 4.5 to 12.7 % [87]. Compared to chil-
dren or younger adults, older adults and/or elderly
subjects have greater morbidity and healthcare costs from
asthma. In a study by Tsai et al. [88], elderly subjects (ages
65 years and older) had fourfold greater overall mortality
than subjects ages 18 to 64.9 years. Therapeutic approach
to asthma in elderly patients does not differ from what is
recommended for young patients, but there have been few
reports regarding the efficacy of therapy in older patients,
and most recommendations are an arbitrary extrapolation
of what has been tested in younger subjects [89]. Monte-
lukast could be of interest in the treatment of asthma in
the elderly, as it could contribute to obtain symptom con-
trol by enhancing patients’adherence, frequently reduced
in the elderly [90]. Elderly patients have usually multiple
comorbid conditions, and they are also prone to have poor
inhaler technique/adherence combined with lack of care-
givers and cognitive impairment [91]. Inhaler misuse is
common in the real-world setting with both pressurized
metered dose inhalers (pMDIs) and dry powder inhalers
(DPIs), and it is associated with poor asthma control [92].
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In elderly patients, the simpler route of administration of
Montelukast, compared with the inhaled agents, could
represent a more effective strategy in improving the out-
comes of asthma therapy, given that unintentional nonad-
herence with inhalation therapy may lead to significant
impairment of asthma symptom control [93]. Recently, Ye
et al. compared, in a randomized, open-label, parallel-
designed trial, the efficacy of the addition of montelukast
to low-dose inhaled budesonide (MON-400 BUD) versus
increasing the dose of inhaled steroid (800 BUD) on
asthma control in older asthmatics. The efficacy of 12-
week treatment with MON-400 BUD in older asthmatics
was comparable to that of 800 BUD on asthma control
but associated with reduced frequency of asthma exacer-
bations requiring oral steroids and sore throat events [94].
Bozek et a. [95] evaluated 512 elderly patients (>60 years
old) with severe asthma over 24 months of therapy: the
first 12 months using inhaled corticosteroids (ICS) and
long-acting beta-agonists (LABA) and the second
12 months with oral montelukast added in two-thirds of
the patients, with the remaining third representing the
control group. During the first year of treatment using
ICS and LABA, an increase in the median percentage of
days without asthma was observed, as well as a decrease
in the percentage of days with short beta-receptor agonist
use. These differences were significantly greater when
montelukast was added to the therapy (78.4 and 39.5 %,
respectively). This improvement was not observed in the
control group. Leukotriene modifiers have been demon-
strated to be safe in elderly asthmatic, even though cases
of acute hepatitis and occurrence of Churg-Strauss syn-
drome have been described; whether this is associated
with age is to be confirmed [89]. Taken together, these ob-
servations are reassuring regarding safe use and efficacy of
montelukast in the management of asthma at advanced
ages, as an add-on treatment to inhaled combination ther-
apy to control the disease or as an alternative to inhaled
corticosteroids or long-acting beta-2 agonists when these
are contraindicated in the elderly population.
“Small airways” phenotypes
Recent studies suggest that persistent uncontrolled in-
flammation in the peripheral small airways can also con-
tribute to clinical expression and worse control of
asthma, with increased asthma symptoms, more severe
bronchial hyper-responsiveness and an increased num-
ber of exacerbations [96]. These findings support the
view that distal lung is a very important target in any
therapeutic strategy for effective treatment. Several stud-
ies have assessed the ability of both inhaled small par-
ticle aerosols and oral treatments to target the distal
airways and improve physiological indices and levels of
asthma control. Montelukast is a systematically adminis-
tered leukotriene receptor antagonist that reaches the
small and large airways [97]. Leukotriene receptors are
differently expressed in fibroblasts from peripheral com-
pared to central airways [98], which may explain a sug-
gested cysteinyl-leukotriene driven remodeling mainly in
the peripheral airways and possibly resulting in a pre-
dominant effect of montelukast on the small airways.
Mechiche et al. reported that the CysLTs were about 30-
fold more potent in small bronchi than in larger bronchi
and that Montelukast exerts a potent antagonist activity
against the particularly potent constricting effects of
CysLTs in isolated human small bronchi [99]. Several
studies showed that biomarkers of peripheral airways are
improved by montelukast: peripheral airways resistance
[100], air trapping [101], and alveolar nitric oxide [102].
There is suggestive evidence that a improvement in dis-
tal dysfunction/inflammation after treatment with mon-
telukast is associated with better asthma control and
asthma-related Quality of Life [103].
Preschool children with asthma and wheezing disorders
Wheezing and shortness of breath in preschool children
are among the most common presenting symptoms in
paediatric practice. Approximately 50 % of children ex-
perience a wheezing illness during the first 6 years of
life, and one-third of young children from the United
States and Europe experienced multiple days troubled by
cough, wheeze, or breathlessness over the preceding 6
winter months [104]. Although about two-thirds of these
children lose their symptoms after the age of 6 years, the
disease places a considerable burden on the child, the
child’s family, and society because of the high prevalence
and lack of good treatment control [105]. While early
transient wheeze is a benign condition, with no sequelae
for respiratory health by age 18, intermediate-onset and
persistent wheeze phenotypes are associated with re-
duced growth in pre-bronchodilator FEV1 over adoles-
cence and sometimes with irreversible airflow limitation
by 18 years [106]. Viral infections account for up to
85 % of childhood asthma exacerbations, daily symp-
toms, and exacerbations in children with asthma [107].
Since 2008, phenotypical classifications proposed by
international paediatric groups, based on the temporality
of symptoms (episodic or persistent) and asthma triggers
(viral only, allergens, exercise, or multitriggers), have
been recommended to better support therapeutic deci-
sions [108]. The typical wheezing pattern in infants and
preschool aged children consists of short but recurrent
exacerbations of cough and wheeze triggered by viral in-
fections and separated by long symptom-free intervals
[109]. A ERS Task Force report [110] recommended dis-
tinguishing between two phenotypes based on temporal
patterns of wheeze:episodic viral wheeze (EVW, wheez-
ing during discrete time periods, often in association
with clinical evidence of a viral cold, with absence of
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wheeze between episodes) and multiple-trigger wheeze
(MTW, wheezing that shows discrete exacerbations, as
with episodic viral wheeze, but also symptoms between
episodes). Both daily ICS and LTRA therapies have shown
efficacy in the management of intermittent wheezing in
preschool children, and intermittent high-dose ICS ther-
apy is comparable in efficacy to daily low-dose ICS ther-
apy in high risk children [109]. Preschool children with a
history of episodic wheezing, who are at high risk for
asthma, but without evidence of day-to-day impairment,
have improved clinical courses in terms of exacerbations
requiring OCS when they receive ICS therapy, either as a
daily low-dose ICS regimen or as an intermittent high-
dose ICS [104, 111]. Despite the established efficacy of
daily low-dose ICS in increasing episode-free days, paren-
tal adherence to such approaches in clinical care is sub-
optimal, likely due to the episodic nature of the disease in
preschool children and concerns surrounding the safety of
ICS therapy [104]. The excellent safety profile of montelu-
kast, and the possibility of oral administration, which en-
tails better compliance from young children, represent the
main strengths of its use in preschool children. Therefore,
montelukast represents an alternative to ICS in poorly
compliant preschool children, or in subjects who show ad-
verse effects related to long-term steroid therapy [112].
Furthermore, evidence suggests that leukotrienes play a
key role in viral-induced respiratory illness [113]. Leuko-
trienes can be detected up to 28 days after the onset of
viral-induced respiratory illness, suggesting the need for
long-term treatment. Clinical trial data in preschool-aged
children with persistent asthma demonstrate that daily
use of montelukast for 12 weeks significantly reduces
asthma symptom frequency, rescue albuterol use, oral cor-
ticosteroid use, and peripheral blood eosinophil counts
[114]. Szefler et al. compared budesonide inhalation sus-
pension (BIS) and montelukast over a 1-year period in 202
children aged 2 to 4 years with mild persistent asthma.
BIS and montelukast provided acceptable asthma control,
with no significant difference between treatments in the
primary end point; however, several secondary outcomes
showed statistically significant differences in favor of
BIS over montelukast [115]. Among 26 preschool-aged
children with mild asthma, montelukast therapy over a
4-week period was associated with a 2.5-fold reduction
in bronchial hyperresponsiveness (BHR) to methacho-
line relative to placebo [116]. Initiation of open label
montelukast in preschool-aged children with persistent
asthma and fraction of exhaled nitric oxide levels of
10 ppb or greater was associated with a significant de-
crease in fraction of exhaled nitric oxide levels, along
with improvements in BHR to adenosine, lung function
(by means of forced oscillation), and symptom scores over
an 8-week period [117] Finally, one study of 194 children
(22 % aged 2 to 5 years) showed that montelukast added
to the usual treatment with ICS reduced the risk of wors-
ening asthma symptoms (53 % less) and unscheduled
physician visits (78 % less) during the annual September
asthma epidemic [114]. Boys aged 2 to 5 years showed
greater benefit from montelukast than did older boys
[118]. The GINA and NAEPP/EPR3 guidelines identify
ICSs as the preferred controller at step 2, with montelu-
kast identified as an alternative in children 0 to 5 years of
age [21, 119]. In a recent report, an international consen-
sus group reviews the new evidence and proposes some
modifications to the recommendations made in 2008
[120]; there was consensus that ICS are the first-choice
maintenance therapy for MTW,while, in EVW with severe
or frequent attacks, either ICS or montelukast may be pre-
scribed. Recently [121], a Cochrane Database Systematic
Review, mainly based on patients in intermittent therapy,
concluded that, in pre-school children with EVW, there is
no evidence of benefit associated with maintenance or
intermittent LTRA treatment, compared to placebo, for
reducing the number of children with one or more viral-
induced episodes requiring rescue oral corticosteroids,
and little evidence of significant clinical benefit for other
secondary outcomes. However, the authors acknowledge
that children with an apparent EVW phenotype are not a
homogeneous group and that subgroups may respond to
LTRA treatment depending on the patho-physiological
mechanisms involved and the genetic background. Re-
cently, Nwokoro et al. [122] showed no clear benefit of
intermittent montelukast in young children with wheeze.
However, the 5/5 ALOX5 promoter genotype might iden-
tify a montelukast-responsive subgroup. In conclusion,
the decision to start any controller therapy in preschool
children is most strongly determined by the pattern, fre-
quency and severity of symptoms. [104] Any preschool
child with troublesome recurrent wheeze could be started
on either ICS (first choice) or montelukast [108, 109].
Safety
Montelukast is generally considered a safe drug with the
occurrence of a few adverse drug reactions (ADRs). The
overall incidence of ADRs due to montelukast, based on
clinical data, suggests that it is comparable to placebo
and its use as add-on therapy does not seem to increase
ADRs in comparison to therapy based on ICS or beta-2
stimulants. Recently, a Systematic Review and Meta-
Analysis compared the efficacy and safety of LTRAs with
placebo in adults and adolescents [19]. The proportions
of patients with adverse events were generally similar in
the intervention and comparator groups. Across all tri-
als, no serious adverse events were reported. Five trials
explicitly reported no adverse events. The Authors con-
cluded that the incidence of adverse events and with-
drawals due to adverse events and worsening asthma
was similar for LTRAs and placebo, which reflects a
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favorable safety and tolerability profile for LTRAs. A re-
view of clinical trials summarized the safety and toler-
ability information for montelukast evaluating data from
2751 paediatric patients (preschool and school children).
Montelukast was well-tolerated, and the most frequent
clinical ADRs noticed in all treatments (placebo, montelu-
kast and active control/usual care) in virtually all studies
were upper respiratory infection, worsening asthma,
pharyngitis, and fever [122]. There is conflicting evi-
dence regarding the association between montelukast and
neuropsychiatric events (NE). Recently, Ali et al. exami-
nated this association among children with asthma and
1920 subjects less than 18 years of age with a primary
diagnosis of asthma between 1 January 1998 and 31
December 2009 were identified. A clear dose-response
relationship was not observed, with an adjusted OR of
1.01 (95 % CI [0.88, 1.14] for experiencing NE [123, 124].
Conclusions
In summary, evidence from real-life studies and rando-
mised controlled trials, show that montelukast (the most
widely used of the LTRAs) is effective on many biological
and pathophysiological mechanisms involved in asthma.
Montelukast, when used as monotherapy or added to in-
haled corticosteroids, is able to reduce rescue treatment
requirements, improve pulmonary function, and reduce
symptoms and risk of exacerbations in adults and children
with asthma. Poor adherence to ICS is common and con-
tributes to worse control of asthma, severe exacerbations,
including hospitalizations and emergency department
visits. The simpler route of administration of Montelukast,
compared with the inhaled agents, could represent a more
effective strategy in improving adherence to asthma ther-
apy. There is a considerable amount of evidence support-
ing the concept that some asthma phenotypes seem
sensitive to montelukast, especially in a real-life setting.
Montelukast has proven to be particularly effective in
exercise-induced asthma and in asthma associated with
allergic rhinitis. Other phenotypes where montelukast is
effective include asthma in obese patients, asthma in
smokers, aspirin-exacerbated respiratory disease and viral-
induced wheezing episodes. At the present time, there is
no phenotypic feature or routinely available laboratory
measure that can definitively predict responsiveness to
anti-LT agents, necessitating the performance of a thera-
peutic trial in individual patients. Montelukast is generally
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